IkT-148009 for Parkinson's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the safety and effects of IkT-148009, a daily pill, in people aged 30 to 80 with untreated Parkinson's disease. The drug aims to block an enzyme that may help manage symptoms. Participants will take the drug for a few months.
Do I need to stop my current medications to join the trial?
Yes, you will need to stop certain medications to join the trial. You cannot be on any anti-parkinsonian therapy, and you must not have taken certain medications like levodopa or monoamine oxidase-B inhibitors within 28 days before screening. If you've used irreversible monoamine oxidase-B inhibitors, they must be stopped at least 90 days before screening.
Who Is on the Research Team?
Milton Werner, PhD
Principal Investigator
ABLi Therapeutics, Inc.
Are You a Good Fit for This Trial?
This trial is for people aged 30-80 with untreated Parkinson's Disease (PD) who meet specific medical criteria and can self-administer a drug daily with food. They must not need other PD treatments during the study, agree to birth control methods if of childbearing potential, and have no significant health issues that could affect participation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive one of three doses of IkT-148009 or placebo once daily for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- IkT-148009
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
ABLi Therapeutics, Inc.
Lead Sponsor
Inhibikase Therapeutics, Inc.
Lead Sponsor